0167/2022 - COVID-19 and breast cancer screening in Brazil: a comparative analysis of the pre-pandemic and pandemic periods COVID-19 e rastreamento do câncer de mama no Brasil: uma análise comparativa dos períodos pré-pandêmico e pandêmico
the aim was to evaluate the impacts of COVID-19 on breast cancer screening in Brazil. Data were collectedthe Ambulatory Information System referring to “bilateral screening mammography”January/2015 to December/2021. Analyzes were performed by region and for Brazil. The average of exams in each month of the year was calculated based on 2015-2019 data, which was compared, monthly, with the amount of exams in 2020 and 2021, obtaining the gross and percentage difference between these values. The same analysis was performed for the total number of exams in 2020 and 2021, individually, and for these two years combined. In 2020 there were reductions in the number of exams, which ranged25% (North) to 48% (Northeast), resulting in 1.749 million exams fewer than expected in the country (a drop of 44%). In 2021, the Midwest region presented a number of exams 11% higher than expected, while the other regions presented drops between 17% (North) and 27% (Southeast/South), resulting in 927 thousand exams fewer than expected in Brazil (reduction of 23%). In the joint analysis (2020/2021), reductions varied by region11% (Midwest) to 35% (Southeast/South), culminating in 2.676 million exams fewer than expected in Brazil (reduction of 33%).
Keywords:
COVID-19; Pandemics; Breast neoplasms; Mass screening.
COVID-19 e rastreamento do câncer de mama no Brasil: uma análise comparativa dos períodos pré-pandêmico e pandêmico
Abstract(resumo):
objetivou-se avaliar os impactos da COVID-19 no rastreamento do câncer de mama no Brasil. Coletaram-se dados do Sistema de Informações Ambulatoriais referentes a “mamografia bilateral para rastreamento” de janeiro/2015 a dezembro/2021. As análises foram feitas por região e para o Brasil. Calculou-se a média de exames em cada mês do ano com base nos dados de 2015 a 2019, a qual foi comparada, mensalmente, com o quantitativo de exames em 2020 e 2021, obtendo-se a diferença bruta e percentual entre esses valores. A mesma análise foi realizada para o número total de exames em 2020 e 2021, individualmente, e para os dois anos em conjunto. Em 2020 houve quedas no número de exames que variaram de 25% (Norte) a 48% (Nordeste), culminando em 1,749 milhão de exames a menos no país (queda de 44%). Em 2021, a região Centro-Oeste apresentou quantitativo de exames 11% superior ao esperado, enquanto as demais regiões apresentaram quedas entre 17% (Norte) e 27% (Sudeste/Sul), culminando em negativo de 927 mil exames no país (redução de 23%). Na análise conjunta (2020/2021), encontraram-se reduções que variaram de 11% (Centro-Oeste) a 35% (Sudeste/Sul), culminando em negativo de 2,676 milhões de procedimentos no Brasil (queda de 33%).
Keywords(palavra-chave):
COVID-19; Pandemia; Neoplasias da mama; Programas de rastreamento.
Furlam, T. O., Gomes, L. M., Machado, C. J.. COVID-19 and breast cancer screening in Brazil: a comparative analysis of the pre-pandemic and pandemic periods. Cien Saude Colet [periódico na internet] (2022/Jul). [Citado em 05/12/2025].
Está disponível em: http://cienciaesaudecoletiva.com.br/en/articles/covid19-and-breast-cancer-screening-in-brazil-a-comparative-analysis-of-the-prepandemic-and-pandemic-periods/18423
